# FutureFuel Corp.: Form 10-Q for the period ended Sep 30, 2011

- Company: [FutureFuel Corp.](/companies/ff.md) (CIK 1337298)
- Form: 10-Q
- Filed: 2011-11-09
- Accepted by EDGAR: Nov 9, 2011, 16:58 ET
- Period: 2011-09-30
- Accession: 0001437749-11-008309
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1337298/000143774911008309/futurefuel_10q-093011.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1337298/000143774911008309/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2011-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2011-07-01 to 2011-09-30 | $90.1m | us-gaap:Revenues |
| Revenue | 9 months, 2011-01-01 to 2011-09-30 | $216.3m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2011-07-01 to 2011-09-30 | $66.6m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 9 months, 2011-01-01 to 2011-09-30 | $168.9m | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months, 2011-07-01 to 2011-09-30 | $22.0m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2011-01-01 to 2011-09-30 | $42.4m | us-gaap:GrossProfit |
| Research and development | 3 months, 2011-07-01 to 2011-09-30 | $996.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2011-01-01 to 2011-09-30 | $2.6m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2011-07-01 to 2011-09-30 | $2.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2011-01-01 to 2011-09-30 | $7.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2011-07-01 to 2011-09-30 | $19.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2011-01-01 to 2011-09-30 | $35.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2011-07-01 to 2011-09-30 | $6.0k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2011-01-01 to 2011-09-30 | $176.0k | us-gaap:InterestExpense |
| Income tax | 3 months, 2011-07-01 to 2011-09-30 | $7.3m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2011-01-01 to 2011-09-30 | $13.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2011-07-01 to 2011-09-30 | $12.7m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2011-01-01 to 2011-09-30 | $23.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2011-07-01 to 2011-09-30 | $0.31 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2011-01-01 to 2011-09-30 | $0.59 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2011-07-01 to 2011-09-30 | $0.31 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2011-01-01 to 2011-09-30 | $0.59 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2011-07-01 to 2011-09-30 | 41,478,005 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2011-01-01 to 2011-09-30 | 40,687,188 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2011-01-01 to 2011-09-30 | $60.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2011-01-01 to 2011-09-30 | $18.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2011-01-01 to 2011-09-30 | $12.1m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | at 2011-09-30 | $102.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2011-09-30 | $230.6m | us-gaap:AssetsCurrent |
| Total assets | at 2011-09-30 | $371.7m | us-gaap:Assets |
| Current liabilities | at 2011-09-30 | $32.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2011-09-30 | $94.4m | us-gaap:Liabilities |
| Shareholders' equity | at 2011-09-30 | $277.4m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 40,893 characters.

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read together with our consolidated financial statements, including the notes thereto, set forth herein. This discussion contains forward-looking statements that reflect our current views with respect to future events and financial performance. Actual results may differ materially from those anticipated in these forward-looking statements. See “Forward Looking Information” below for additional discussion regarding risks associated with forward-looking statements.

### Results of Operations

#### In General

We break our chemicals business into two main product groups: custom manufacturing and performance chemicals. Custom manufacturing consists of products made for specific customers based upon specifications provided by such customers. Major products in the custom manufacturing group include: (i) nonanoyloxybenzene-sulfonate, a bleach activator manufactured exclusively for The Procter & Gamble Company for use in a household detergent and (ii) a proprietary herbicide (and intermediates) manufactured exclusively for Arysta LifeScience Corporation. The custom manufacturing group also includes agrochemicals as well as industrial and consumer products (cosmetics and personal care products, ink colorants, adhesion promoters, polymer additives, polymer and specialty dyes, specialty polymers, photographic and imaging chemicals, and food additives).

Revenues generated from the bleach activator are based on a supply agreement with the customer. The supply agreement stipulates selling price per kilogram based on volume sold, with price moving up as volumes move down, and vice-versa. The current contract expires in March 2013. We pay for raw materials required to produce the bleach activator. The contract with the customer provides that the price received by us for the bleach activator is indexed to changes in certain items, enabling us to pass along most inflationary increases in production costs to the customer. In the second quarter of 2011, we received notification from the customer of the bleach activator stating their intention to reduce the quantities of the bleach activator they purchase beginning as soon as possible from the date of such notice. The amount of such decrease was not stated. We continue to work collaboratively with our customer to assess their future demand, which demand may continue to decline. The financial impact of any such decline is not known at this time.

We have been the primary manufacturer for our customer of a proprietary herbicide and certain intermediates. These products are facing generic competition, and no assurances can be given that we will remain the primary manufacturer for this product line. The contract automatically renews for successive one-year periods, subject to the right of either party to terminate the contract not later than 270 days prior to the end of the then current term. No assurances can be given that this contract will not be terminated. The customer supplies most of the key raw materials for production of the proprietary herbicide. There is no pricing mechanism or specific protection against cost changes for raw materials or conversion costs that we are responsible for purchasing and/or providing.

In 2008, we entered into a contract with a new customer for the toll manufacture of an industrial intermediate utilized in the antimicrobial industry. We invested approximately $10 million in capital expenditures to modify and expand our plant to produce this industrial intermediate. The customer reimbursed these expenditures, which reimbursements have been classified as deferred revenue on our balance sheet and will be earned into income over the expected life of the customer relation. The contract stipulates a price curve based on volumes sold and has an inflationary pricing provision whereby we pass along most inflationary changes in production costs to the customer. The contract expires in December 2013.

Pricing for the other custom manufacturing products is negotiated directly with the customer. Some, but not all, of these products have pricing mechanisms and/or protections against raw material or conversion cost changes.

Performance chemicals consist of specialty chemicals that are manufactured to general market-determined specifications and are sold to a broad customer base. The major product line in the performance chemicals group is SSIPA/LiSIPA, a polymer modifier that aids the properties of nylon. This group of products also includes sulfonated monomers and hydrotropes, specialty solvents, polymer additives, and chemical intermediates.

SSIPA/LiSIPA revenues are generated from a diverse customer base of nylon fiber manufacturers and other customers that produce condensation polymers. Contract sales are indexed to key raw materials for inflation; otherwise, there is no pricing mechanism or specific protection against raw material or conversion cost changes.

Pricing for the other performance chemical products is established based upon competitive market conditions. Some, but not all, of these products have pricing mechanisms and/or specific protection against raw material or conversion cost changes.

We procure all of our own feedstock and only sell biodiesel for our own account. In rare instances, we purchase biodiesel from other producers for resale. We have the capability to process multiple types of vegetable oils and animal fats, we can receive feedstock by rail or truck, and we have completed the construction of substantial storage capacity to acquire feedstock at advantaged prices when market conditions permit. In 2009, we completed a project to increase our production nameplate capacity to 59 million gallons of biodiesel per year through the addition of a new continuous processing line. We initiated commercial production from this new line in May 2009. By the end of the second quarter of 2009, daily production volumes from the new processing line were demonstrated at approximately 80% of nameplate capacity. This production line was designed to produce biodiesel from feedstock with low fatty acids. We believe we successfully demonstrated our ability to keep this continuous processing line at or near capacity for sustained periods of time as well as our ability to procure and logistically handle large quantities of feedstock with low fatty acids. However, with the expiration of the $1.00 federal blenders’ credit at the end of 2009, we determined that feedstock with low fatty acids were too costly to consistently produce biodiesel with positive margins. Accordingly, we redesigned our continuous line to produce biodiesel from feedstock with high fatty acids. We are currently producing at approximately 50% of our nameplate capacity of 59 million gallons per year in the continuous production line. We are still in the process of debugging and optimizing the production process to increase the output of the plant. When economically advantageous, we may also place batch reactors into service to increase our biodiesel production capabilities. Such reactors are more expensive to operate than the continuous production line and can only produce biodiesel from a limited assortment of feedstocks.

There currently is uncertainty as to whether we will produce biodiesel in the future. This uncertainty results from: (i) changes in feedstock prices relative to biodiesel prices; (ii) continuance of the $1.00 per gallon federal blenders’ tax credit, which credit terminates on December 31, 2011; and (iii) the permanency of government mandates. See “Risk Factors” below.

While biodiesel is the principal component of the biofuels segment, we also generate revenue from the sale of petrodiesel both in blends with our biodiesel and, from time to time, with no biodiesel added. Petrodiesel and biodiesel blends are available to customers at our leased storage facility in North Little Rock, Arkansas. In addition, we deliver blended product to a small group of customers within our region. We also sell refined petroleum products from time to time to maintain our status as a shipper on a common carrier pipeline.

The majority of our expenses are cost of goods sold. Cost of goods sold include raw material costs as well as both fixed and variable conversion costs, conversion costs being those expenses that are directly or indirectly related to the operation of our plant. Significant conversion costs include labor, benefits, energy, supplies, depreciation, and maintenance and repair. In addition to raw material and conversion costs, cost of goods sold includes environmental reserves and costs related to idle capacity. Finally, cost of goods sold includes hedging gains and losses recognized by us related to our biofuels segment. Cost of goods sold is allocated to the chemicals and biofuels business segments based on equipment and resource usage for most conversion costs and based on revenues for most other costs.

Operating costs include selling, general and administrative, and research and development expenses.

The discussion of results of operations that follows is based on revenues and expenses in total and for individual product lines and do not differentiate related party transactions.

#### Three Months Ended September 30, 2011 Compared to Three Months Ended September 30, 2010

#### Revenues

Revenues for the three months ended September 30, 2011 were $90,307,000 as compared to revenues for the three months ended September 30, 2010 of $66,093,000, an increase of 37%. Revenues from our biofuels segment increased 155% and accounted for 53% of total revenues in 2011 as compared to 29% in 2010. Revenues from our chemicals segment decreased 11% and accounted for 47% of total revenues in 2011 as compared to 71% in 2010.

Historically, the revenues from the bleach activator and the proprietary herbicide and intermediates together have been the most significant components of our revenue base. In the three months ended September 30, 2011, these products accounted for 31% of revenues as compared to 47% for the three months ended September 30, 2010. Revenue from the bleach activator decreased approximately 17% in the third quarter of 2011 as compared to the third quarter of 2010. We are unable to predict with certainty the revenues we will receive from this product in the future as the customer has stated that they intend to decrease purchases for the remainder of this year and next year and the price for such decreased purchases has not been finalized between us and our customer. Further, the future volumes of and revenues from the bleach activator depend on both consumer demand for the product containing the bleach activator and the manufacturing, sales, and marketing priorities of our customer. With respect to the proprietary herbicide and intermediates, revenues increased approximately 6% in the third quarter of 2011 as compared to the third quarter of 2010. Expectations are that the demand for the herbicide will remain strong in the foreseeable future.

Revenues from other custom chemical products decreased approximately 29% in the third quarter of 2011 as compared to the third quarter of 2010. This decrease was almost entirely due to production ceasing on one product which we campaigned for a customer in 2010. This first campaign ended in the first quarter of 2011. A second campaign for this same customer was started in October 2011. Revenues from proprietary chemicals increased approximately 13% in the three months ended September 30, 2011 compared to the three months ended September 30, 2010. This increase was due to sales of new performance chemicals, including crude glycerin, and increased sales of SSIPA.

Revenues from biofuels increased from $18,884,000 in the third quarter of 2010 to $48,123,000 in the third quarter of 2011, an increase of 155%. The reinstatement of the $1.00 per gallon federal blender’s credit in December 2010 along with the government mandated renewable fuel standard combined to improve the economics of biodiesel, and demand and production increased in 2011 relative to 2010. However, no assurances can be given that the blender’s credit will be extended past the end of this year or that the government mandated renewable fuel standard will not be repealed or phased out. Additionally, we continued to develop our regional fuel distribution business. However, a substantial portion of our biodiesel sold in the third quarter of 2011 was to a major refiner in the United States and no assurances can be given that we will continue to sell to such major refiner or, if we do sell, the volume that will be sold or the profit margin that will be realized.

#### Cost of Goods Sold and Distribution

Cost of goods sold and distribution for the three months ended September 30, 2011 totaled $68,312,000. This represented an increase of 26% over the third quarter of 2010.

Cost of goods sold and distribution for the three months ended September 30, 2011 for our chemicals segment were $29,120,000 as compared to cost of goods sold and distribution for the three months ended September 30, 2010 of $33,920,000, a decrease of 14%. On a percentage basis, the 14% decrease in cost of goods sold and distribution was slightly more than the 11% decrease in chemicals segment revenues. This difference is attributable to differences in product mix from 2010 to 2011 and from the increase in biofuel related sales, which causes a higher percentage of our fixed costs to be allocated to the biofuels segment. These items are partially offset by expenses we were unable to pass along to customers.

Cost of goods sold and distribution for the third quarter of 2011 for our biofuels segment totaled $39,192,000 as compared to cost of goods sold and distribution for the third quarter of 2010 of $20,297,000, an increase of 93%. On a percentage basis, cost of goods sold and distribution increased 93% versus an increase in revenues of 155%. This difference is largely attributable to our receipt of approximately $1,900,000 awarded to us under the USDA Section 9005 – Advanced Biofuel Producers program in the third quarter of 2011. This award totaled $100,000 for the comparable period in the prior year. Based on the characteristics of the award, we recognize the income from it in the period funding is received. Additionally, the $1.00 per gallon federal blender’s credit existed in the third quarter of 2011 and it did not exist in the third quarter of 2010. The existence of this credit is a significant factor in the profitability of biodiesel production. Both the USDA Section 9005 – Advanced Biofuel Producers grant and the $1 per gallon federal blender's credit are recorded as a reduction to our cost of goods sold and distribution expenses in our consolidated statement of operations and comprehensive income. We continue to acquire feedstock and produce biodiesel as this credit is effective through December 31, 2011. If the credit is not extended beyond the end of this year, our biofuels segment could be materially and adversely affected.

#### Operating Expenses

Operating expenses increased 13% from $2,340,000 for the three months ended September 30, 2010 to $2,637,000 in the three months ended September 30, 2011, an increase of $297,000. This increase is primarily attributable to an increase in our research and development expenses.

#### Provision for Income Taxes

The effective tax rates for the three months ended September 30, 2011 and 2010 reflect our expected tax rate on reported operating earnings before income taxes. We have determined that we do not believe that we have a more likely than not probability of realizing a portion of our deferred tax assets. As such, we have recorded a valuation allowance of $397,000 at September 30, 2011 and $277,000 at December 31, 2010.

#### Nine Months Ended September 30, 2011 Compared to Nine Months Ended September 30, 2010

Revenues for the nine months ended September 30, 2011 were $220,276,000 as compared to revenues for the nine months ended September 30, 2010 of $165,570,000, an increase of 33%. Revenues from our biofuels segment increased 180% and accounted for 44% of total revenues in 2011 as compared to 21% in 2010. Revenues from our chemicals segment decreased 6% and accounted for 56% of total revenues in 2011 as compared to 79% in 2010.

Historically, the revenues from the bleach activator and the proprietary herbicide and intermediates together have been the most significant components of our revenue base. In the nine months ended September 30, 2011, these products accounted for 36% of revenues as compared to 52% for the nine months ended September 30, 2010. Revenue from the bleach activator decreased approximately 18% in the first three quarters of 2011 as compared to the first three quarters of 2010. We are unable to predict with certainty the revenues we will receive from this product in the future as the customer has stated that they intend to decrease purchases for the remainder of this year and next year and the price for such decreased purchases has not been finalized between us and our customer. Further, the future volumes of and revenues from the bleach activator depend on both consumer demand for the product containing the bleach activator and the manufacturing, sales, and marketing priorities of our customer. With respect to the proprietary herbicide and intermediates, revenues increased approximately 13% in the first three quarters of 2011 as compared to the first three quarters of 2010. Expectations are that the demand for the herbicide will remain strong in the foreseeable future.

Revenues from other custom chemical products decreased approximately 22% in the first three quarters of 2011 as compared to the first three quarters of 2010. While increases and decreases in the sales activities of several products contributed to this fluctuation, the decrease was mostly due to production ceasing on one product which we campaigned for a customer in 2010. This first campaign ended in the first quarter of 2011. A second campaign for this same customer was started in October 2011. Revenues from proprietary chemicals increased approximately 24% in the nine months ended September 30, 2011 compared to the nine months ended September 30, 2010 due to sales of new performance chemicals, including crude glycerin, and increased sales of existing performance chemicals, most notably SSIPA.

Revenues from biofuels increased from $34,504,000 in the first three quarters of 2010 to $96,545,000 in the first three quarters of 2011, an increase of 180%. The reinstatement of the $1.00 per gallon federal blender’s credit in December 2010 along with the government mandated renewable fuel standard combined to improve the economics of biodiesel, and demand and production increased in 2011 relative to 2010. However, no assurances can be given that the blender’s credit will be extended past the end of this year or that the government mandated renewable fuel standard will not be repealed or phased out. Additionally, we continued to develop our regional fuel distribution business. However, a substantial portion of our biodiesel sold in the first three quarters of 2011 was to a major refiner in the United States and no assurances can be given that we will continue to sell to such major refiner or, if we do sell, the volume that will be sold.

#### Cost of Goods Sold and Distribution

Cost of goods sold and distribution for the nine months ended September 30, 2011 totaled $177,853,000. This represented an increase of 28% over the nine months ended September 30, 2010.

Cost of goods sold and distribution for the nine months ended September 30, 2011 for our chemicals segment were $95,824,000 as compared to cost of goods sold and distribution for the nine months ended September 30, 2010 of $99,845,000, a decrease of 4%. On a percentage basis, the 4% decrease in cost of goods sold and distribution was slightly less than the 6% decrease in chemicals segment revenues. This difference is attributable to differences in product mix from 2010 to 2011 and from the increase in biofuel related sales, which causes a higher percentage of our fixed costs to be allocated to the biofuels segment. These items are partially offset by expenses we were unable to pass along to customers.

Cost of goods sold and distribution for the first three quarters of 2011 for our biofuels segment totaled $82,029,000 as compared to cost of goods sold and distribution for the first three quarters of 2010 of $39,606,000, an increase of 107%. On a percentage basis, cost of goods sold and distribution increased 107% versus an increase in revenues of 180%. This difference is largely attributable to our receipt of approximately $1,900,000 awarded to us under the USDA Section 9005 – Advanced Biofuel Producers program in the third quarter of 2011. This award totaled $100,000 for the comparable period in the prior year. Based on the characteristics of the award, we recognize the income from it in the period funding is received. Additionally, the $1.00 per gallon federal blender’s credit existed in the third quarter of 2011 and it did not exist in the third quarter of 2010. The existence of this credit is a significant factor in the profitability of biodiesel production. Both the USDA Section 9005 – Advanced Biofuel Producers grant and the $1 per gallon federal blender's credit are recorded as a reduction to our cost of goods sold and distribution expenses in our consolidated statement of operations and comprehensive income. We continue to acquire feedstock and produce biodiesel as this credit is effective through December 31, 2011. If the credit is not extended beyond the end of this year, our biofuels segment could be materially and adversely affected.

#### Operating Expenses

Operating expenses increased 10% from $6,563,000 for the nine months ended September 30, 2010 to $7,189,000 in the nine months ended September 30, 2011, an increase of $626,000. This increase is primarily attributable to the increase in compensation expense, which increased from $2,270,000 in the first three quarters of 2010 to $2,955,000 in the first three quarters of 2011. This increase in compensation expense was primarily the result of $502,000 in expense being recognized in the first three quarters of 2011 for stock option compensation expense. Options for 120,000 shares of stock were granted in the second quarter of 2011. No such options were granted in the first three quarters of 2010.

#### Provision for Income Taxes

The effective tax rates for the nine months ended September 30, 2011 and 2010 reflect our expected tax rate on reported operating earnings before income taxes. We have determined that we do not believe that we have a more likely than not probability of realizing a portion of our deferred tax assets. As such, we have recorded a valuation allowance of $397,000 at September 30, 2011 and $277,000 at December 31, 2010.

#### Critical Accounting Estimates

#### Revenue Recognition

For most product sales, revenue is recognized when product is shipped from our facilities and risk of loss and title have passed to the customer, which is in accordance with our customer contracts and the stated shipping terms. Nearly all custom manufactured products are manufactured under written contracts. Performance chemicals and biodiesel are generally sold pursuant to the terms of written purchase orders. In general, customers do not have any rights of return, except for quality disputes. However, all of our products are tested for quality before shipment, and historically returns have been inconsequential. We do not offer volume discounts, rebates, or warranties.

Revenue from bill and hold transactions in which a performance obligation exists is recognized when the total performance obligation has been met. Bill and hold transactions for four specialty chemical customers in the nine months ended September 30, 2011 and 2010 related to revenue that was recognized in accordance with contractual agreements based on product produced and ready for use. These sales were subject to written monthly purchase orders with agreement that production was reasonable. The inventory was custom manufactured and stored at the customer’s request and could not be sold to another buyer. Credit and payment terms for bill and hold customers are similar to other specialty chemical customers. Sales revenue under bill and hold arrangements were $15,305,000 and $14,948,000 for the three months ended September 30, 2011 and 2010, respectively, and $47,201,000 and $41,412,000 for the nine months ended September 30, 2011 and 2010, respectively.

### Liquidity and Capital Resources

Our net cash provided by (used in) operating activities, investing activities, and financing activities for the nine months ended September 30, 2011 and 2010 are set forth in the following chart.

(Dollars in thousands)

|  | Nine Months Ended September 30, 2011 | Nine Months Ended September 30, 2010 |
| --- | ---: | ---: |
| Net cash provided by operating activities | $60,111 | $17,509 |
| Net cash (used in) investing activities | $(52,284) | $(25,919) |
| Net cash provided by financing activities | $3,672 | $46,433 |

#### Operating Activities

Cash provided by operating activities increased from $17,509,000 during the first nine months of 2010 to $60,111,000 during the first nine months of 2011, an increase of $42,602,000. This increase was largely due to changes in accounts receivable, accounts payable, income taxes payable, deferred revenues and net income. Partially offsetting the positive impact in cash provided by operating activities for these items was an increase in inventory. In the first nine months of 2010, accounts receivable reduced cash provided by operating activities by $5,091,000, and in 2011 increased cash provided by operating activities by $9,318,000. This increase was primarily attributable to the collection of the $1.00 per gallon federal blender’s credit, which was booked as an account receivable at December 31, 2010 and collected in the first quarter of 2011. The effect of this collection has been partially offset by higher accounts receivable balances from biodiesel customers, which resulted from our increased biodiesel sales activity. In the first nine months of 2010, accounts payable used $2,202,000 of cash from operations. In the first nine months of 2011, accounts payable provided $655,000. This increase in cash provided to operating activities is largely due to timing differences related to the receipt and payment of inventory and the timing of payment for capital expenditures. In the first nine months of 2010, income taxes payable did not affect cash provided by operating activities and income taxes receivable reduced cash provided by operating activities by $609,000. In the first nine months of 2011, income taxes payable increased cash provided by operating activities by $4,570,000 and income taxes receivable increased cash provided by operating activities by $519,000. This increase was largely due to timing associated with our income tax payments. Additionally, as our net income has increased, the amount of these tax payments has increased. In the first nine months of 2011, deferred revenue contributed $11,743,000 to cash provided by operating activities. In the first nine months of 2010, it contributed $5,252,000. This change is a result of progress made on capital projects we have undertaken on behalf of certain of our customers. Lastly, $10,915,000 of the increase in cash provided by operating activities is due to the increase in net income in the first three quarters of 2011 as compared to net income in the first three quarter of 2010.

#### Investing Activities

Cash used in investing activities increased from $25,919,000 in the nine months ended September 30, 2010 to $52,284,000 in the nine months ended September 30, 2011. This increase is primarily attributable to a reduction in restricted cash, a net increase in the purchases of marketable securities, and an increase in capital expenditures. In the first nine months of 2011, our restricted cash balances decreased by $21,086,000. This reduction resulted from our short sale position in U.S. Treasuries having been closed. When this happened, the cash which was previously held in a restricted margin account was returned to us. In the first nine months of 2011, we purchased a net $52,371,000 of marketable securities. Such purchases totaled a net $18,866,000 in the first nine months of 2010. Lastly, capital expenditures for the first nine months of 2011 totaled $18,849,000 compared to $6,063,000 in the first nine months of 2010. This increase in capital expenditures is primarily the result of us undertaking certain capital projects on behalf of certain customers, a large portion of which is reimbursed by certain of our customers and through grants. These reimbursements are summarized in the following table.

(Dollars in thousands)

|  | Nine Months Ended September 30, 2011 | Nine Months Ended September 30, 2010 |
| --- | ---: | ---: |
| Capital expenditures | $18,849 | $6,063 |
| Cash received as reimbursement of capital expenditures | (10,807) | (1,609) |
| Net cash paid for capital expenditures | $8,042 | $4,454 |

#### Financing Activities

Cash provided by financing activities decreased from $46,433,000 in the first nine months of 2010 to $3,672,000 in the first nine months of 2011. This decrease was primarily attributable to the difference in proceeds from equity issuances in the two periods. In the first nine months of 2010, $70,700,000 of cash was received as a result of certain warrant holders exercising their warrants to acquire our common stock, which was partially offset by $1,210,000 used to purchase and cancel certain other outstanding warrants. In the first nine months of 2011, $15,798,000 was received primarily as a result of the at-the-market offering of our common stock which commenced on June 3, 2011, as discussed below. Additionally in the first nine months of 2011, we paid dividends of $12,126,000; in the first nine months of 2010 such activities totaled $23,057,000.

#### At-the-Market Offering

On February 10, 2011, we filed with the United States Securities and Exchange Commission, or SEC, a Form S-3 Registration Statement commonly referred to as a “shelf-registration” whereby we registered shares of our common stock, preferred stock, warrants, rights, and units which we might issue in the future in an aggregate amount not to exceed $50 million. The registration statement was amended on March 4, 2011 and became effective on March 10, 2011.

On May 10, 2011, we entered into an At-the-Market Equity Offering Sales Agreement with Stifel, Nicolaus & Company, Incorporated, or Stifel, relating to up to 3 million shares of our common stock. The sales of shares of our common stock under this sales agreement are to be made in “at the market” offerings as defined in Rule 415 of the Securities Act of 1933, as amended, including sales made directly on the New York Stock Exchange (the principal existing trading market for shares of our common stock), to or through a market maker or any other trading market for our common stock, or (with our prior consent) in privately negotiated transactions at negotiated prices. The aggregate compensation payable to Stifel as sales agent will be 3% of the gross sales price of the shares sold through the sales agreement. The sales are being made pursuant to our shelf registration.

We commenced sales of our common stock through this at-the-market offering on June 3, 2011. The number of shares of our common stock sold through Stifel under the sales agreement, the net proceeds to us, and the compensation paid by us to Stifel in connection with the sales of our common stock during the second quarter of 2011 are set forth in the following table.

| Number of Shares Sold | Net Proceeds | Compensation to Stifel |
| ---: | ---: | ---: |
| 1,313,985 | $15,763,000 | $488,000 |

19

We did not make any sales of our common stock through this at-the-market offering during the third quarter of 2011.

#### Credit Facility

We entered into a $50 million credit agreement with a commercial bank in March 2007. The loan is a revolving facility the proceeds of which may be used for our working capital, capital expenditures, and general corporate purposes. The facility terminates on June 30, 2013. Advances are made pursuant to a borrowing base. Advances are secured by a perfected first priority security interest in our accounts receivable and inventory. The interest rate floats at certain margins over LIBOR or base rate based upon the leverage ratio from time to time. There is an unused commitment fee. The ratio of total funded debt to EBITDA may not be less than 3:1. We had no borrowings under this credit agreement at September 30, 2011 or December 31, 2010.

We intend to fund future capital requirements for our businesses from cash flow generated by us as well as from existing cash and cash investments, proceeds from our at-the-market offering, and borrowings under the credit facility. We do not believe there will be a need to issue any securities to fund such capital requirements other than those which may be sold through our at-the-market offering.

#### Dividends

In the first quarter of 2011, we declared a special cash dividend in the amount of $0.10 per share on our common stock, with a record date of March 1, 2011 and a payment date of March 15, 2011. The special cash dividend amounted to approximately $3,998,000.

On April 5, 2011, we declared normal quarterly cash dividends of $0.10 per share on our common stock for the remainder of 2011, with record dates of June 1, 2011, September 1, 2011, and December 1, 2011, and payment dates of June 14, 2011, September 15, 2011, and December 15, 2011. The regular cash dividends for June 2011 amounted to approximately $3,998,000 and for September 2011 amounted to approximately $4,130,000.

#### Capital Management

As a result of our initial equity offering, our subsequent positive operating results, the exercise of warrants, and our at-the-market offering, we accumulated excess working capital. Some of this excess working capital has been paid out as special and regular cash dividends. We intend to retain the remaining cash to fund infrastructure and capacity expansion at our Batesville plant, to pursue complimentary acquisitions in the energy and chemical industries, and to pay the regular cash dividends for the remainder of 2011. Third parties have not placed significant restrictions on our working capital management decisions.

These funds were predominantly held in cash or cash equivalents at multiple financial institutions. In the first three quarters of 2011 and 2010, we also had investments in certain preferred stock, trust preferred securities, and other equity instruments. We classify these investments as current assets in the accompanying consolidated balance sheets and designate them as being “available-for-sale”. Accordingly, they are recorded at fair value, with the unrealized gains and losses, net of taxes, reported as a component of stockholders’ equity. The fair value of these preferred stock, trust preferred securities, and other equity instruments, including accrued interest, totaled $56,270,000 and $28,200,000 at September 30, 2011 and December 31, 2010, respectively.

At December 31, 2010, we also had a short position in certain marketable debt securities. The purpose of this position was to help mitigate the potential negative impact an increase in interest rates would have on other marketable securities we had purchased. The securities comprising this position are carried at fair value, with unrealized gains and losses reported as a component of net income. We realized losses of $170,000 on these securities in the first three quarters of 2011. No such losses were recognized in the first nine months of 2010. This position was closed in the first half of 2011 and no short position in these marketable debt securities was present at September 30, 2011. The fair value of these securities totaled $(19,295,000) at December 31, 2010. The margin account maintained with a broker to collateralize these securities carried a balance of $21,086,000 at December 31, 2010, and was classified as restricted cash and cash equivalents in our consolidated balance sheet.

Lastly, we maintain depositary accounts such as checking accounts, money market accounts, and other similar accounts at selected financial institutions.

### Off-Balance Sheet Arrangements

We engage in two types of hedging transactions. First, we hedge our biofuels sales through the purchase and sale of futures contracts and options on futures contracts of energy commodities. This activity was captured on our balance sheet at September 30, 2011 and December 31, 2010. Second, we hedge our biofuels feedstock through the execution of purchase contracts and supply agreements with certain vendors. These hedging transactions are not recognized in earnings and were not recorded on our balance sheet at September 30, 2011 or December 31, 2010 as they do not meet the definition of a derivative instrument as defined under accounting principles generally accepted in the U.S. The purchase of biofuels feedstock generally involves two components: basis and price. Basis covers any refining or processing required as well as transportation. Price covers the purchases of the actual agricultural commodity. Both basis and price fluctuate over time. A supply agreement with a vendor constitutes a hedge when we have committed to a certain volume of feedstock in a future period and have fixed the basis for that volume.

At December 31, 2010, we had a short position in certain marketable debt securities. The purpose of this position was to help mitigate the potential negative impact an increase in interest rates would have on other marketable securities we have purchased. We were committed to repurchase these short-sold securities in the future. We were required to maintain a margin account at a broker to collateralize this obligation. It was possible that this margin account balance would not have been sufficient to meet our obligation, which would have placed an additional commitment on our available cash balances.

From time to time we may enter into forward sales commitments related to our generation of renewable identification numbers, or RINs. At the time these commitments are made, we may or may not have these RINs in our possession, but expect to generate them in the ordinary course of our biodiesel business. These commitments are not reflected on our consolidated balance sheet. If we are unable to generate enough RINs to meet these obligations, we may be forced to purchase replacement RINs from other parties. Such activity may result in us purchasing RINs at a higher price than we have agreed to sell them for.

### Other Matters

We entered into an agreement with a customer to construct, at a fixed price, a processing plant and produce a certain chemical for the customer. We engaged a third party to act as general contractor on the construction of this plant for a guaranteed price. That general contractor defaulted on its obligations under its contract with us and abandoned the project. As a result, we undertook the general contractor role ourselves. We also filed suit against our former contractor to recoup any damages that we may incur as a result of his default. The former contractor counterclaimed against us for amounts he asserts are due him under our contract with him. At this time, we are unable to determine what effect the general contractor’s counterclaim will have on us or on our financial condition.

We entered into an agreement with a biodiesel trade association to pay certain fees and dues to the association in order to obtain access and registration to the association’s compiled biodiesel health effects data, or HED, required by the Environmental Protection Agency for biodiesel manufacturers. Manufacturers of biodiesel who pay their fair share of costs for the HED can have access to and obtain registration with the Environmental Protection Agency. We brought suit against the trade association for rescission of the agreement for various reasons including, among other things, that we have already paid our fair share of costs for the data to the trade association; and that the fees and dues structure of the trade association are overly excessive and against public policy. The trade association filed suit against us for collection of alleged fees and dues owed by us to it. At this time, we are unable to determine what effect the trade association’s suit against us will have on us or on our financial condition.

## Market risk

As filed, 5,414 characters.

In recent years, general economic inflation has not had a material adverse impact on our costs and, as described elsewhere herein, we have passed some price increases along to our customers. However, we are subject to certain market risks as described below.

Market risk represents the potential loss arising from adverse changes in market rates and prices. Commodity price risk is inherent in the chemical and biofuels business both with respect to input (electricity, coal, biofuel feedstock, etc.) and output (manufactured chemicals and biofuels).

We seek to mitigate our market risks associated with the manufacturing and sale of chemicals by entering into term sale contracts that include contractual market price adjustment protections to allow changes in market prices of key raw materials to be passed on to the customer. Such price protections are not always obtained, however, so raw material price risk remains significant.

In order to manage price risk caused by market fluctuations in biofuel prices, we may enter into exchange traded commodity futures and options contracts. We account for these derivative instruments in accordance with ASC 815-20-25, *Derivatives and Hedging, Hedging-General, Recognition.* Under this standard, the accounting for changes in the fair value of a derivative instrument depends upon whether it has been designated as an accounting hedging relationship and, further, on the type of hedging relationship. To qualify for designation as an accounting hedging relationship, specific criteria must be met and appropriate documentation maintained. We had no derivative instruments that qualified under these rules as designated accounting hedges in the first three quarters of 2011 or 2010. Changes in the fair value of our derivative instruments are recognized at the end of each accounting period and recorded in the statement of operations as a component of cost of goods sold.

Our immediate recognition of derivative instrument gains and losses can cause net income to be volatile from quarter to quarter due to the timing of the change in value of the derivative instruments relative to the sale of biofuel being sold. As of September 30, 2011 and December 31, 2010, the fair values of our derivative instruments were a net liability in the amount of $2,706,000 and $1,649,000, respectively.

Our gross profit will be impacted by the prices we pay for raw materials and conversion costs (costs incurred in the production of chemicals and biofuels) for which we do not possess contractual market price adjustment protection. These items are principally comprised of animal fat, electricity, and petrodiesel. The availability and price of these items are subject to wide fluctuations due to unpredictable factors such as weather conditions, overall economic conditions, governmental policies, commodity markets, and global supply and demand.

We prepared a sensitivity analysis of our exposure to market risk with respect to key raw materials and conversion costs for which we do not possess contractual market price adjustment protections, based on average prices for the first nine months of 2011. We included only those raw materials and conversion costs for which a hypothetical adverse change in price would result in a 1% or greater decrease in gross profit. Assuming that the prices of the associated finished goods could not be increased and assuming no change in quantities sold, a hypothetical 10% change in the average price of the commodities listed below would result in the following change in annual gross profit:

(Volumes and dollars in thousands)

| Item | Volume(a) Requirements | Units | Hypothetical Adverse Change in Price | Decrease in Gross Profit | Percentage Decrease in Gross Profit |
| --- | ---: | --- | ---: | ---: | ---: |
| Biodiesel feedstock | 115,479,865 | LB | 10% | $5,012 | 11.8% |
| Ultra low sulphur diesel | 3,452,036 | GAL | 10% | $998 | 2.4% |
| Electricity | 72,737 | MWH | 10% | $413 | 1.0% |

(a) Volume requirements and average price information are based upon volumes used and prices obtained for the nine months ended September 30, 2011. Volume requirements may differ materially from these quantities in future years as our business evolves.

We had no borrowings as of September 30, 2011 or December 31, 2010 and, as such, were not exposed to interest rate risk for those periods. Due to the relative insignificance of transactions denominated in foreign currency, we consider our foreign currency risk to be immaterial.

At December 31, 2010, we had a short position in certain marketable debt securities. The purpose of this position was to help mitigate the potential negative impact an increase in interest rates would have on our other marketable securities. The fair value of these securities totaled $(19,295,000) at December 31, 2010. We maintained a margin account to collateralize these marketable debt securities. This margin account maintained a balance of $21,086,000 at December 31, 2010, and was classified as restricted cash and cash equivalents in our consolidated balance sheet included herein. We were obligated to purchase these securities at a future date. To the extent that these marketable debt securities appreciated in value, we were exposed to off-balance sheet risks. These securities were repurchased in the first six months of 2011 and this position did not exist at September 30, 2011.

## Controls and procedures

As filed, 1,103 characters.

Under the supervision and with the participation of our chief executive officer and our principal financial officer and other senior management personnel, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15(d)-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of the end of the period covered by this report. Based on that evaluation, our chief executive officer and our principal financial officer have concluded that these disclosure controls and procedures as of September 30, 2011 were effective to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms.

There were no changes in our internal control over financial reporting during our last fiscal quarter that materially affected, or were reasonably likely to materially affect, our internal control over financial reporting.

### PART II

### OTHER INFORMATION

## Risk factors

As filed, 253 characters.

This section could not be read just now; read it on sec.gov.

Filed Nov 9, 2011.
Source: SEC EDGAR, the filing index for accession 0001437749-11-008309. Last ingested by Listed: Nov 14, 2026, 19:59 ET. No prices; not investment advice.
